This is a working overview of NADH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-26. Anything still debated is marked as such rather than presented as settled.
NAD+ is commonly measured by high-performance liquid chromatography with ultraviolet detection, often at 254 or 260 nm. Enzymatic cycling assays provide higher sensitivity by coupling NAD+ to a reporter reaction. Mass spectrometry can distinguish NAD+ from close analogues and confirm isotope labeling. Sample preparation usually involves rapid quenching of metabolism to prevent interconversion with NADH. Because NAD+ and NADH differ by one hydride, extraction conditions strongly affect the measured ratio.
In aqueous solution, NAD+ is most stable under mildly acidic to neutral conditions and degrades faster at high pH or elevated temperature. The molecule can hydrolyze at the pyrophosphate bond or undergo nonenzymatic cyclization. Buffers, chelating agents, and cold temperatures slow these losses during analysis. Repeated freeze-thaw cycles are generally avoided because they can promote degradation and concentration changes. Light exposure is also controlled, though NAD+ is less photolabile than some related nucleotides.
Beyond redox chemistry, NAD+ serves as a substrate for enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins, PARPs, and CD38-family enzymes consume NAD+ and produce nicotinamide and ADP-ribose-related products. These reactions link NAD+ availability to DNA repair, chromatin modification, and cellular signaling. Because the molecule is central to energy metabolism and regulation, changes in its concentration are studied in aging, immunity, and metabolic research. The balance between synthesis and consumption varies by tissue, developmental stage, and physiological state.
In humans, NAD+ can be synthesized from nicotinic acid, nicotinamide, nicotinamide riboside, and tryptophan through overlapping pathways. The salvage pathway recycles nicotinamide back to NAD+ and is often considered a major route in many tissues. Dietary precursors and intracellular recycling both contribute to the pool, but the quantitative importance of each source remains an active research question. NAD+ levels are not uniform across organs or cell compartments. Measurements in blood do not necessarily reflect concentrations inside tissues.
| Property | Value | Notes |
|---|---|---|
| UV absorption maximum | 259–260 nm | Aqueous solution; pH-dependent |
| Common salt form | Disodium salt | Improves aqueous solubility |
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | HPLC with UV detection | Often paired with mass spectrometry |
| Aqueous stability | pH and temperature dependent | Degrades faster at alkaline pH and high heat |
NAD+ stands for nicotinamide adenine dinucleotide, the oxidized form of a coenzyme found in all living cells. The molecule consists of two nucleotides, adenine and nicotinamide ribose, joined through phosphate groups. Its chemical formula is C21H27N7O14P2, and the free acid has a molar mass near 663.43 grams per mole. In redox reactions, NAD+ accepts a hydride ion and becomes NADH. The pair NAD+ and NADH participates in hundreds of metabolic reactions, including steps in glycolysis, the citric acid cycle, and oxidative phosphorylation.
In cells, NAD+ functions primarily as an electron carrier. Dehydrogenase enzymes in glycolysis and the citric acid cycle transfer hydride from substrates to NAD+, producing NADH. NADH then delivers electrons to the mitochondrial respiratory chain, supporting ATP synthesis. In fermentation, NADH is reoxidized to NAD+ so that glycolysis can continue. The balance between NAD+ and NADH helps set metabolic flux. Beyond redox, NAD+ serves as a substrate for enzymes that cleave it, including sirtuins, poly(ADP-ribose) polymerases, and CD38. These reactions consume NAD+ and release nicotinamide and ADP-ribose products.
Biosynthesis occurs through salvage, Preiss-Handler, and de novo pathways. In mammals, the salvage pathway from nicotinamide predominates, and NAMPT is often described as rate-limiting. Nicotinamide riboside and nicotinic acid enter related routes that converge on NAD+ production. Tissue NAD+ concentrations vary widely and are maintained by a balance of synthesis and consumption. Some studies report age-related declines in certain tissues, but whether these changes cause disease or can be reversed to improve human health remains an open question.
In glycolysis, NAD+ accepts electrons during the oxidation of glyceraldehyde-3-phosphate, forming NADH. The tricarboxylic acid cycle and fatty acid oxidation also generate NADH, which donates electrons to the mitochondrial electron transport chain. This flow supports ATP synthesis and helps maintain the redox balance of the cell. Other dehydrogenases use NAD+ as a cofactor for biosynthetic reductions and detoxification reactions. NADH is later reoxidized to sustain continued flux through these pathways.
Beyond electron transfer, NAD+ serves as a substrate for enzymes that cleave the molecule and transfer ADP-ribose units. Sirtuins, poly(ADP-ribose) polymerases, and CD38 consume NAD+ in regulatory reactions. These activities link NAD+ availability to DNA repair, chromatin modification, calcium signaling, and metabolic stress responses. Because consumption can exceed biosynthesis under some conditions, cellular NAD+ levels are dynamic rather than fixed. Enzyme affinity and local synthesis also influence how much NAD+ is available for signaling.
NAD+ is a dinucleotide composed of adenine, ribose, and nicotinamide moieties linked by phosphate groups. Its oxidized form carries a positive charge on the nicotinamide ring, which enables reversible hydride transfer. The molecule functions as a coenzyme in oxidoreductase reactions rather than as a dietary vitamin in its intact form. Cells maintain separate pools in cytoplasm, mitochondria, and nucleus. This compartmentalization allows distinct redox environments while preserving a shared chemical identity.
This is interpreted by some researchers to mean that although the incorporation of lactobacillic acid into the cell membrane has no significant influence on the physical properties of the membrane, it does change its chemical properties, which is an advantage for the organism. One example of a beneficial effect of lactobacillic acid is provided by Oenococcus oeni. The lactic acid bacterium is used in wine production to convert malic acid into lactic acid during malolactic fermentation into lactic acid, which in turn is converted into ethanol by baker's yeast. In this way, the acidity of the wine is reduced. In the process, Oenococcus oeni is exposed to relatively high concentrations of ethanol produced by yeasts during alcoholic fermentation. Studies of the cell membrane of the bacterium have shown that the biosynthesis rate of phospholidides is increased with increasing ethanol concentration in the surrounding culture medium. In addition, more lactobacillic acid is formed in the membrane lipids, while the content of cis vaccenic acid decreases. This is interpreted as a protective mechanism against the toxic effects of ethanol. The formation of lactobacillic acid helps the bacterium to adapt to unfavorable environmental conditions. A similar protective effect was discovered in L. delbrueckii subsp. bulgaricus. It shows improved survivability against freeze-drying when more lactobacillic acid is present in the cell membrane.
He explored this topic in his book Panic Nation (2006), which he co-authored with Stanley Feldman. Marks gained prominence in the medico-legal field, providing expert opinions in notable cases. His testimony in Danish-born British socialite Claus von Bülow's 1985 trial challenged accusations of insulin injection and led to an acquittal. The case was made into a book and later into an Oscar winning movie, Reversal of Fortune. In his testimony, Marks said that the insulin-covered needle was most likely planted by someone who did not realize that insulin is cleaned off the needles once it is injected. Marks also testified against Beverley Allitt in 1993, who used insulin to murder four children, and at the trial of Colin Norris in 2008. In 2007, he co-authored Insulin Murders detailing his involvement in high-profile medico-legal cases and reflecting on his career. The book was among the first to talk about insulin as a murder weapon and documented more than 50 years of medical cases in which insulin had been used as a weapon. Marks retired in 1995 but remained active as an emeritus professor, contributing to research, publishing, and medico-legal work. He served as the president at the Association of Clinical Biochemists between 1989 and 1991, and as the vice president at the Royal College of Pathologists. In a career spanning more than 50 years, he authored over 50 papers, contributed to more than 300 research publications, and authored almost 20 textbooks. His last book, The Forensic Aspects of Hypoglycaemia, was published in 2019.
Members of the Organic Anion Transporter (OAT) Family (organic-anion-transporting polypeptides, OATP) are membrane transport proteins or 'transporters' that mediate the transport of mainly organic anions across the cell membrane. Therefore, OATPs are present in the lipid bilayer of the cell membrane, acting as the cell's gatekeepers. OATPs belong to the Solute Carrier Family (SLC) and the major facilitator superfamily. The generalized transport reactions catalyzed by members of the OAT family are: Anion (in) → Anion (out) Anion1 (in) + Anion2 (out) → Anion1 (out) + Anion2 (in)
On March 5, 1946, Winston Churchill, while at Westminster College in Fulton, Missouri, gave his speech "The Sinews of Peace", declaring that an "iron curtain" had descended across Europe. From the standpoint of the Soviets, the speech was an incitement for the West to begin a war with the USSR, as it called for an Anglo-American alliance against the Soviets.
Sources: en.wikipedia.org
== History == The 5-HT2c receptor agonist Fenfluramine (market names Pondimin, Ponderax and Adifax) was discovered in 1972 as a result of research performed to identify anorectic compounds lacking the effects of psycho-stimulants and sympathomimetic agents (such as amphetamines). Prior to the discovery of fenfluramine, amphetamines were the primary form of anorectic drugs available, however the side effects made them difficult to use. Fenfluramine's anorectic effect is achieved through an increase in serotonin levels, imparting a sensation of fullness, which leads to a lower intake of food. Fenfluramine was sold as a racemic mixture of two enantiomers, dexfenfluramine and levofenfluramine. In 1994, sales of the combination drug Fen-phen (fenfluramine and phentermine) increased dramatically, as this combination produced substantial and apparent synergistic effect in promoting weight loss. Subsequently, reports of severe side effects associated with heart valve abnormalities and an increased risk of pulmonary hypertension resulted in a decision to remove products containing fenfluramine from the U.S. market, and then from other markets around the world. Dexfenfluramine inhibits serotonin reuptake, stimulating the release of serotonin. In 1996, dexfenfluramine became the first long-term treatment anti-obesity medication approved in the US; adverse effects observed during clinical trials included dry mouth, diarrhea and drowsiness. In the mid-1990s the US FDA approved dexfenfluramine as a weight loss drug.
=== Dihydrolipoyl dehydrogenase (E3) === The dihydrolipoate, covalently bound to a lysine residue of the complex, is then transferred to the Dihydrolipoyl dehydrogenase (E3) active site, where it undergoes a flavin-mediated oxidation, similar in chemistry to e.g. thioredoxin reductase. First, FAD oxidizes dihydrolipoate back to its lipoate (disulfide) resting state, producing FADH2. Then, the substrate NAD+ oxidizes FADH2 back to its FAD resting state, producing NADH and H+.
=== Seizures === Phenobarbital is used in the treatment of all types of seizures, except absence seizures. It is no less effective at seizure control than phenytoin, but phenobarbital is not as well tolerated. Phenobarbital may provide a clinical advantage over carbamazepine for treating partial seizures. Carbamazepine may provide a clinical advantage over phenobarbital for generalized tonic–clonic seizures. The first-line drugs for treatment of status epilepticus are benzodiazepines, such as lorazepam, clonazepam, midazolam, or diazepam. If these fail, then phenytoin may be used, with phenobarbital being an alternative in the US (favored in infants), but used only third-line in the UK. Failing that, the only treatment is anesthesia in intensive care. The World Health Organization (WHO) gives phenobarbital a first-line recommendation in the developing world and it is commonly used there. Phenobarbital is the first-line choice for the treatment of neonatal seizures. Concerns that neonatal seizures in themselves could be harmful make most physicians treat them aggressively. However, no reliable evidence supports this approach.
Sources: en.wikipedia.org
NAD+ and NADH can interconvert quickly after a sample is collected, which can alter the measured ratio. Rapid quenching and cold handling limit enzymatic and chemical changes.
Purity is often checked by HPLC with UV detection, sometimes paired with mass spectrometry for identity. An assay against a standard can quantify the active cofactor content.
Solid NAD+ is usually kept dry, cold, and protected from light. Aqueous working solutions are best prepared fresh because degradation depends on pH, temperature, and time.
The plus sign indicates the oxidized form of nicotinamide adenine dinucleotide, which can accept electrons. When it accepts electrons, it becomes NADH. The two forms together support redox reactions in cells.